2015 Rue Peel 5eme Etage
Montréal, QC, H3A 1T8 Canada
(514) 336-7800 †
Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies received US approval for EGRIFTS in 2010 and approval in Canada and Mexico in 2015. The drug is marketed solely in the US (in partnership with
† Some telephone numbers on the Hoover’s site may be on a country’s do not call or do not contact list including, but not limited to, the United Kingdom’s CTPS or TPS registers. It is a legal requirement that companies do not make sales or marketing calls to registered numbers. These are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls. By using the information provided on the Hoover’s sites, as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local, state, national or international laws and regulations, including any local do not call registers or marketing regulations, and agree to defend, indemnify and hold harmless Dun & Bradstreet and each of its affiliates in the event your use violates such laws and regulations.